Trial · NCT02428296
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA | Affected Tissue | Run-in period | 7.9 | Standard Deviation 12.8 | mean percentage change in tissue volume |
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA | Unaffected Tissue | Run-in period | 4.8 | Standard Deviation 9.7 | mean percentage change in tissue volume |
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA | Affected Tissue | Treatment period | 0.71 | Standard Deviation 10.2 | mean percentage change in tissue volume |
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA | Unaffected Tissue | Treatment period | 6.5 | Standard Deviation 12.3 | mean percentage change in tissue volume |
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA | Affected Tissue | Change in mean percentage change of tissue volume | -7.2 | Standard Deviation 16.0 | mean percentage change in tissue volume |
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA | Unaffected Tissue | Change in mean percentage change of tissue volume | 1.7 | Standard Deviation 11.5 | mean percentage change in tissue volume |
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by MRI Scan | Affected Tissue | -3.7 | Standard Deviation 12.3 | percentage of tissue volume change | |
| Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by MRI Scan | Unaffected Tissue | 0 | Standard Deviation 16.7 | percentage of tissue volume change | |
| Mean Sirolimus Doses to Achieve the Target Plasma Concentration | PIK3CA-Related Overgrowth Spectrum Patients | Adults | 1.2 | 95% Confidence Interval 1.1 to 1.3 | mg/day |
| Mean Sirolimus Doses to Achieve the Target Plasma Concentration | PIK3CA-Related Overgrowth Spectrum Patients | Children | 1.16 | 95% Confidence Interval 1.0 to 1.3 | mg/day |
| Additional Measure of Efficacy: Quality of Life Assessment | Patients With PIK3CA Gene Mutation Treated With Sirolimus | Children (total health) | -1.7 | 95% Confidence Interval -5.0 to 8.8 | mean change in quality of life score |
| Additional Measure of Efficacy: Quality of Life Assessment | Patients With PIK3CA Gene Mutation Treated With Sirolimus | Parents (total health) | 4.9 | 95% Confidence Interval -0.7 to 10.4 | mean change in quality of life score |
| Additional Measure of Efficacy: Quality of Life Assessment | Patients With PIK3CA Gene Mutation Treated With Sirolimus | Adults (physical health) | 0.25 | 95% Confidence Interval -8.9 to 9.4 | mean change in quality of life score |
| Additional Measure of Efficacy: Quality of Life Assessment | Patients With PIK3CA Gene Mutation Treated With Sirolimus | Adults (psychological health) | -1.25 | 95% Confidence Interval -7.3 to 4.8 | mean change in quality of life score |
| Additional Measure of Efficacy: Quality of Life Assessment | Patients With PIK3CA Gene Mutation Treated With Sirolimus | Adults (social relationships) | 6.3 | 95% Confidence Interval -1.8 to 14.3 | mean change in quality of life score |
| Additional Measure of Efficacy: Quality of Life Assessment | Patients With PIK3CA Gene Mutation Treated With Sirolimus | Adults (environment) | -7.3 | 95% Confidence Interval -32.5 to 17.7 | mean change in quality of life score |
| Number of Hospitalizations and Surgical Interventions | PIK3CA-Related Overgrowth Spectrum Patients | Run-in period : Hospitalizations | 5 | number of events | |
| Number of Hospitalizations and Surgical Interventions | PIK3CA-Related Overgrowth Spectrum Patients | Run-in period : Surgical interventions | 2 | number of events | |
| Number of Hospitalizations and Surgical Interventions | PIK3CA-Related Overgrowth Spectrum Patients | Treatment period : Hospitalizations | 9 | number of events | |
| Number of Hospitalizations and Surgical Interventions | PIK3CA-Related Overgrowth Spectrum Patients | Treatment period : Surgical interventions | 0 | number of events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02428296/results